PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.4851
+0.0171 (3.65%)
At close: Aug 29, 2025, 4:00 PM
0.4950
+0.0099 (2.04%)
After-hours: Aug 29, 2025, 7:42 PM EDT
PAVmed Revenue
PAVmed had revenue of $6.00K in the quarter ending June 30, 2025, a decrease of -99.39%. This brings the company's revenue in the last twelve months to $1.02M, down -73.36% year-over-year. In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth.
Revenue (ttm)
$1.02M
Revenue Growth
-73.36%
P/S Ratio
6.28
Revenue / Employee
$26,154
Employees
39
Market Cap
8.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.00M | 543.00K | 22.15% |
Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PAVM News
- 2 days ago - Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 - PRNewsWire
- 3 days ago - PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology - PRNewsWire
- 15 days ago - PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 16 days ago - Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 24 days ago - Lucid Diagnostics to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025 - PRNewsWire
- 4 weeks ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - PRNewsWire
- 4 weeks ago - PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PRNewsWire